Monoclonal Cell Line and Chemically Defined Medium
Support your virus production with a scalable suspension platform
Overcome the limitations of traditional egg-based methods with a robust and flexible solution for virus and influenza vaccine production.
The MDCK Suspension Platform is designed to meet your needs as the demand for efficient and reliable vaccines continues to grow:
- Monoclonal Suspension MDCK Cell Line
- 4Cell® MDXK CD Medium: A chemically defined, serum-free, animal component-free, and hydrolysate-free medium
- Support services: Cell bank testing, biosafety testing, and characterization
Adapted directly to suspension culture
Fully compliant with regulatory agencies standards for RCB and MCB testing, ensuring the highest levels of safety and quality. Supported by a comprehensive cell line history report, it offers full traceability, making it the ideal choice for vaccine production needs.
Demonstrated versatility in the production of various influenza strains recommended by WHO
Extends production capacities with reduced footprint and simpler scale-up
MDCK Suspension Platform
Monoclonal Suspension MDCK Cell Line
Suspension cells offer flexibility while simplifying scale-up and reducing labor requirements. The cells are adapted directly without genetic modifications or using animal-derived serum and overcome the limitations of traditional egg-based platforms for manufacturing influenza vaccines.
MDCK suspension cell line is available in multiple grades:
- R&D grade for discovery phase
- GMP grade for clinical and commercial phases (available in early 2025)
4Cell® MDXK Chemically Defined Medium for MDCK Cells
MDCK Suspension Cell Line is designed to grow in 4Cell® MDXK CD Medium, a high-quality medium that removes batch-to-batch variations and is formulated without serum, hydrolysates, or components of animal origin.
To simplify scale-up, 4Cell® MDXK CD Medium comes in multiple packaging sizes and formats, including bottles, bags, and powder, with customizable options available upon request.
The medium is ready-to-use, 100% chemically defined, serum-free, animal component-free, and hydrolysate-free.
Ready-to-use medium available in liquid and powder format.
Outsource your Cell Bank and Biosafety Testing to Sartorius
To meet safety standards and ensure product quality, it’s critical to have access to fully characterized, well-documented, and homogeneous master cell banks.
Sartorius has extensive experience in the characterization of cell banks trusted by developers to produce biologics worldwide.
- Closed-system manufacturing
- Comprehensive biosafety testing
- Dedicated cleanroom facility for mammalian cell lines in suspension, manufactured using serum-free, animal component-free media
Scalable Suspension Platform from R&D to GMP Grade
Find the right solution for your stage of development.
R&D Cells
For rapid and efficient screening, the platform is available in R&D grade, for research use only.
GMP Cells
For clinical and commercial phases, we offer GMP-grade cells tailored with the best-fitted package of 4Cell® MDXK CD Medium.
Learn More About MDCK Suspension Platform
The First Commercialized Suspension Platform for MDCK
To achieve flexible and efficient vaccine production that enhances patient safety, while matching the latest regulatory standards, vaccine developers need a platform without the risks of egg- and serum-based methods. MDCK Platform is the first commercialized solution guaranteeing the above while increasing the scalability in process thanks to a monoclonal MDCK suspension cell line. Benefit from Sartorius recognized expertise and be supported in both upstream and downstream.
